Quick Answer
GYRE THERAPEUTICS, INC. reported Research And Development Expense of $13.70 million for the year ending 2025.
- GYRE THERAPEUTICS, INC. showed an increase of +13.9% in Research And Development Expense from 2024 to 2025.
- This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2011: $23.52 million | Q2 2011: $20.19 million | Q3 2011: $25.44 million | Q1 2012: $17.80 million | Q2 2012: $12.51 million | Q3 2012: $6.43 million | Q1 2013: $8.32 million | Q2 2013: $9.45 million | Q3 2013: $10.31 million | Q1 2014: $9.08 million | Q2 2014: $5.41 million | Q3 2014: $1.34 million | Q1 2015: $1.38 million | Q2 2015: $1.32 million | Q3 2015: $1.49 million | Q1 2016: $2.29 million | Q2 2016: $2.75 million | Q3 2016: $3.40 million | Q1 2017: $2.06 million | Q2 2017: $3.40 million | Q3 2017: $3.81 million | Q1 2018: $3.77 million | Q2 2018: $3.89 million | Q3 2018: $5.58 million | Q1 2019: $12.03 million | Q2 2019: $11.11 million | Q3 2019: $9.93 million | Q1 2020: $13.26 million | Q2 2020: $12.91 million | Q3 2020: $12.25 million | Q1 2021: $17.01 million | Q2 2021: $15.39 million | Q3 2021: $20.35 million | Q1 2022: $9.70 million | Q2 2022: $1.87 million | Q3 2022: $803.0 thousand | Q1 2023: $2.64 million | Q2 2023: $3.57 million | Q3 2023: $3.01 million | Q1 2024: $2.18 million | Q2 2024: $3.36 million | Q3 2024: $2.78 million | Q1 2025: $3.10 million | Q2 2025: $3.43 million | Q3 2025: $2.36 million.
- Over the full 16 years of available data (2009 to 2025), GYRE THERAPEUTICS, INC.'s Research And Development Expense has declined by 65.9%.
- Historical annual values: Fiscal year 2025: $13.70 million | Fiscal year 2024: $12.02 million | Fiscal year 2023: $13.78 million | Fiscal year 2021: $68.89 million | Fiscal year 2020: $52.98 million | Fiscal year 2019: $43.86 million | Fiscal year 2018: $21.47 million | Fiscal year 2017: $12.85 million | Fiscal year 2016: $11.56 million | Fiscal year 2015: $5.96 million | Fiscal year 2014: $5.27 million | Fiscal year 2013: $6.56 million | Fiscal year 2012: $49.09 million | Fiscal year 2011: $95.22 million | Fiscal year 2010: $64.55 million | Fiscal year 2009: $40.18 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: